Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression

NCT06756035 is registered in ClinicalTrials.gov with Context Therapeutics Inc. as lead sponsor.

NCT NCT06756035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06756035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1a/1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression
Lead sponsor
Context Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 31, 2025
Completion date
December 31, 2028
Enrollment
70 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma advanced, cholangiocarcinoma non-resectable, colorectal cancer, epithelial ovarian cancer, lung adenocarcinoma metastatic, malignant peritoneal mesothelioma, advanced, malignant pleural mesothelioma, advanced, mesothelin-expressing advanced cancers, mesothelin-expressing tumors, mesothelin-positive advanced malignant solid tumors, pancreatic adenocarcinoma advanced or metastatic